	SEC	Form	4
--	-----	------	---

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.					
1. Name and Address of Reporting Person [*] <u>KRANZLER JAY D</u>		2. Issuer Name and Ticker or Trading Symbol <u>AVENUE THERAPEUTICS, INC.</u> [ATXI]		ionship of Reporting Perso all applicable) Director	n(s) to Issuer 10% Owner
	Middle)	3. Date of Earliest Transaction (Month/Day/Year) 11/05/2024		Officer (give title below)	Other (specify below)
C/O AVENUE THERAPEUTICS, INC. 1111 KANE CONCOURSE SUITE 301		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi X	dual or Joint/Group Filing (Form filed by One Repo	rting Person
(Street) BAY HARBOR ISLANDS FL	33154			Form filed by More than	One Reporting Person
	Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Ir 8)		4. Securities A Disposed Of (D		3, 4 and 5) Securities Form: Direct (D) Beneficially Owned Following Reported Transaction(s)		Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price			(Instr. 4)
COMMON STOCK, PAR VALUE \$0.0001	11/05/2024		S		61	D	\$2.24	559	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	 3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		5. Num Derivat Securit Acquire or Disp (D) (Ins and 5)	ive ies ed (A) osed of	6. Date Exerc Expiration Da (Month/Day/)	ate	7. Title and A Securities U Derivative So (Instr. 3 and	nderlying ecurity	8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		

Explanation of Responses:

/s/ David Jin, Attorney-in-Fact

** Signature of Reporting Person

<u>11/07/2024</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.